Press release – 26.06.2017

Theraclion Announces FDA Authorization to Start U.S. Trial for Immunotherapy and Echotherapy Combination on Breast Cancer


Study led by University of Virginia aims to extend the benefits of immunotherapy in cases of metastatic breast cancer via the combined effects of echotherapy and pembrolizumab


THERACLION today announced its long-term academic partner, University of Virginia (UVA), has received authorization from the U.S. Food and Drug Administration (FDA) to proceed with a new clinical study to evaluate the potential of treatment combining echotherapy (also known as High Intensity Focused Ultrasound, HIFU) with pembrolizumab, a modern immunotherapy drug targeting PD-1 checkpoint Inhibitor.


Read the press release

Print Friendly